|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2004-11-11
|
|
pubmed:abstractText |
HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
pubmed-author:Andrews IiiC WebsterCW3rd,
pubmed-author:BooneLawrence RLR,
pubmed-author:ChanJoseph HJH,
pubmed-author:CowanJill RJR,
pubmed-author:CreechKatrina LKL,
pubmed-author:FerrisRob GRG,
pubmed-author:FreemanGeorge AGA,
pubmed-author:GonzalesStephen SSS,
pubmed-author:HazenRichard JRJ,
pubmed-author:HopkinsAndrew LAL,
pubmed-author:KoszalkaGeorge WGW,
pubmed-author:LowellGina SGS,
pubmed-author:MiltonJohnJ,
pubmed-author:RenJingshanJ,
pubmed-author:ReynoldsDavid JDJ,
pubmed-author:RobertsGrace BGB,
pubmed-author:SchallerLee TLT,
pubmed-author:ShortSteven ASA,
pubmed-author:StammersDavid KDK,
pubmed-author:StuartDavid IDI,
pubmed-author:WeaverKurtK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
18
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5923-36
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15537347-Anti-HIV Agents,
pubmed-meshheading:15537347-Benzoxazines,
pubmed-meshheading:15537347-Binding Sites,
pubmed-meshheading:15537347-Cell Line,
pubmed-meshheading:15537347-Crystallography, X-Ray,
pubmed-meshheading:15537347-Drug Design,
pubmed-meshheading:15537347-Drug Resistance, Viral,
pubmed-meshheading:15537347-HIV Reverse Transcriptase,
pubmed-meshheading:15537347-HIV-1,
pubmed-meshheading:15537347-Humans,
pubmed-meshheading:15537347-Models, Molecular,
pubmed-meshheading:15537347-Molecular Structure,
pubmed-meshheading:15537347-Mutation,
pubmed-meshheading:15537347-Oxazines,
pubmed-meshheading:15537347-Quinolones,
pubmed-meshheading:15537347-Reverse Transcriptase Inhibitors,
pubmed-meshheading:15537347-Structure-Activity Relationship
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
|
|
pubmed:affiliation |
GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, USA. Andy.A.Freeman@gsk.com
|
|
pubmed:publicationType |
Journal Article
|
